October 11, 2012

Update from Vanderbilt Pharmacy and the Department of Infection Control and Prevention about the Nationwide Meningitis Outbreak

Yesterday, Ameridose LLC., a pharmaceutical manufacturing facility partially owned by one of the individuals who also co-owns the New England Compounding Center, the compounding pharmacy at the center of the nationwide meningitis outbreak, voluntarily halted operations so that Massachusetts state inspectors could monitor processing procedures at the Ameridose facility. There has been no product recall and there have been no adverse issues reported with products produced by Ameridose. The voluntary closure of Ameridose is precautionary and is intended to offer assurance products produced at this facility remain safe.

VUMC is one of many U.S. and Nashville health care providers supplied with medications manufactured by Ameridose LLC. While there have been no safety issues reported with products produced by Ameridose, the voluntary closure of the company's processing facility is welcomed so that further reassurance of the facility's safety can be ascertained.

In partnership with VUMC's physicians, the administration of its hospitals and clinics and its clinical staff, Vanderbilt pharmacists are closely monitoring progress of the inspection of the Ameridose facility, along with other aspects of the nationwide fungal meningitis outbreak to fully ensure the continued safety of all VUMC patients.

We have the capacity and will begin to internally produce (compound) the same medications supplied by Ameridose.

In cooperation with the Tennessee Department of Health, the Tennessee Poison Center is the designated call center to address questions from the public about the meningitis outbreak. Members of the public can be directed to call (800) 222-1222 and press Option 1 to be connected with a poison information specialist.

Information for clinicians from the Department of Infection Control & Prevention regarding the fungal meningitis outbreak: The department’s website provides guidance for patient evaluation for suspected fungal meningitis and also a link to the most current information from the Centers for Disease Control and Prevention.